Coherus Oncology (CHRS) Stock Price, Quote, News & History | Benzinga

Coherus Oncology Inc (CHRS) Stock Price, Quote, News & History

CHRSNASDAQ

Trade with Public

Trade with Public

$1.63

At close: Jul 10, 5:00 PM EST

$1.63

N/A

After Hours: 4:02 PM EST

OverviewNews Earnings Events Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 1.16M

Day Range

- - -

52 Wk Range

0.80 - 2.62

Market Cap

$251.43M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

17.13%

Days to Cover

33.41

Recent Coherus Oncology Inc News

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

Rishabh Mishra

Why Coherus BioSciences Stock Is Climbing Today

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.

Erica Kollmann

S&P 500, Nasdaq Set For Wobbly Open As Santa Claus Rally Fades: Analyst Sees Final Trading Sessions As 'Last Great Buying Opportunity'

U.S. stocks may face challenges in maintaining their upward momentum on Wednesday, as index futures suggest a flat start. In the absence of significant catalysts, the market might experience a lack of direction, especially given the low trading volume typical of the holiday period, which could cast doubt on any substantial moves in either direction.

Shanthi Rexaline

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-170.57M

Investing Cash Flow (TTM)

423.23M

Financing Cash Flow (TTM)

-219.85M

Free Cash Flow (TTM)

-170.57M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

32.80M

Analyst Trends and Forecast

1

Jan

1

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$124.38M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.25

PB Ratio (TTM)

3.20

Earnings Yield % (TTM)

-87.12%

Earnings Yield % (FWD)

-67.48%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.51

Company Debt

Total Debt

$37.15M

LT Debt

$37.15M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$115.24M

Debt to Equity

0.51

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / 1.16M

Day Range

- - -

52 Wk Range

0.80 - 2.62

Market Cap

$251.43M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

17.13%

Days to Cover

33.41

About

Sector

Health Care

Industry

Biotechnology

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and o...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Coherus Oncology (CHRS) stock?

A

You can purchase shares of Coherus Oncology (NASDAQ:CHRS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Coherus Oncology (CHRS) competitors?

A

There are no as such competitors for Coherus Oncology.

Q

What is the forecast, or price target, for Coherus Oncology (CHRS) stock?

A

Coherus Oncology has a consensus price target of $7.34.

Q

What is the current price for Coherus Oncology (CHRS)?

A

The stock price for Coherus Oncology (NASDAQ: CHRS) is $1.63 last updated July 9, 2026 at 4:02 PM EDT.

Q

Does Coherus Oncology (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus Oncology.

Q

When is Coherus Oncology (NASDAQ:CHRS) reporting earnings?

A

Coherus Oncology does not have any upcoming earnings scheduled.

Q

Is Coherus Oncology (CHRS) going to split?

A

There is no upcoming split for Coherus Oncology.

Q

What sector and industry does Coherus Oncology (CHRS) operate in?

A

Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.